Bayer

News

Genetic testing hopes to speed up drug development in rare eye diseases

Oxurion reports stronger data for diabetic eye disease drug

Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with

News

FDA fast tracks Bayer's oral anticoagulant asundexian

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

News

Bayer's pipeline takes a hit as it drops eliapixant

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds.

News

Bayer-led project on AI in trials eyes 'virtual' placebo gro...

Last year, Bayer launched a project to explore the use of artificial intelligence in clinical trials, working with Finlan

News

Roche grabs FDA okay for would-be blockbuster eye drug faric...

The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea.

News

FDA stifles Merck's cough drug gefapixant, asking for more d...

The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close th

Oxurion reports stronger data for diabetic eye disease drug

FDA fast tracks Bayer's oral anticoagulant asundexian

Bayer's pipeline takes a hit as it drops eliapixant

Bayer-led project on AI in trials eyes 'virtual' placebo gro...

Roche grabs FDA okay for would-be blockbuster eye drug faric...

FDA stifles Merck's cough drug gefapixant, asking for more d...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Bayer

Editor's Picks